| Index | — | P/E | 4.46 | EPS (ttm) | 0.50 | Insider Own | 4.23% | Shs Outstand | 217.90M | Perf Week | 0.00% |
| Market Cap | 485.91M | Forward P/E | — | EPS next Y | -0.46 | Insider Trans | -0.02% | Shs Float | 176.68M | Perf Month | -12.89% |
| Enterprise Value | 160.91M | PEG | — | EPS next Q | -0.09 | Short Float | 24.22% | Perf Quarter | -32.83% | ||
| Income | -17.00M | P/S | 6.39 | EPS this Y | — | Short Ratio | 12.82 | Perf Half Y | -46.65% | ||
| Sales | 76.00M | P/B | 1.61 | EPS next Y | — | ROA | -20.89% | Short Interest | 42.79M | Perf YTD | -47.65% |
| Book/sh | 1.39 | P/C | 1.47 | EPS next 5Y | — | ROE | -38.46% | 52W High | 8.21 -72.84% | Perf Year | -33.03% |
| Cash/sh | 1.51 | P/FCF | — | EPS past 3/5Y | — | ROIC | -25.42% | 52W Low | 2.14 4.21% | Perf 3Y | 97.35% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 12.77% 2.25% | Gross Margin | 98.63% | Volatility | 7.81% 6.62% | Perf 5Y | -58.16% |
| Dividend TTM | — | EV/Sales | 2.12 | EPS Y/Y TTM | -178.11% | Oper. Margin | -476.19% | ATR (14) | 0.17 | Perf 10Y | -82.65% |
| Dividend Ex-Date | — | Quick Ratio | 9.36 | Sales Y/Y TTM | -87.23% | Profit Margin | -435.21% | RSI (14) | 38.79 | Recom | 2.19 |
| Dividend Gr. 3/5Y | — | Current Ratio | 9.36 | EPS Q/Q | — | SMA20 | -6.28% | Beta | 2.25 | Target Price | 8.50 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | -94.74% | SMA50 | -20.51% | Rel Volume | 2.62 | Prev Close | 2.34 |
| Employees | 69 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -42.29% | Avg Volume | 3.61M | Price | 2.23 |
| IPO Date | Oct 08, 2015 | Option/Short | No / Yes | EPS/Sales Surpr. | -16.76% -88.55% | Net Debt/EBITDA | — | Volume | 9,469,880 | Change | -4.70% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-19-26 | Initiated | Wolfe Research | Outperform | $6.00 |
| May-11-26 | Reiterated | HC Wainwright & Co. | Buy | $11 |
| Mar-18-26 | Reiterated | Jefferies | Buy | $8.00 |
| Mar-16-26 | Reiterated | Oppenheimer | Perform | $7.00 → $12 |
| Mar-16-26 | Upgrade | JP Morgan | Neutral → Overweight | |
| Feb-04-26 | Reiterated | Barclays | Overweight | $8.00 → $10 |
| Jan-20-26 | Initiated | Guggenheim | Buy | $10 |
| Jan-20-26 | Reiterated | Barclays | Overweight | $6.00 → $8.00 |
| Jan-20-26 | Reiterated | Piper Sandler | Overweight | $3.25 → $10 |
| Oct-21-25 | Reiterated | Barclays | Overweight | $3.50 → $6.00 |
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 76 | 138 | 101 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 76 | 138 | 101 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 30 | 30 | 30 | — | — | — | — | — | — | |
| Research and Development | 69 | 83 | 78 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -22 | 25 | -6 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | 7 | 10 | — | — | — | — | — | — | |
| Net Income Before Taxes | -17 | 32 | 3 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 4 | — | — | — | — | — | — | |
| Consolidated Net Income | -17 | 32 | -1 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -17 | 32 | -1 | — | — | — | — | — | — | |
| Net Income | -17 | 32 | -1 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.15 | 0.38 | -0.01 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.15 | 0.38 | -0.01 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.15 | 0.38 | -0.01 | — | — | — | — | — | — | |
| EBITDA | -16 | 34 | 5 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 2.71 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.74 | 0.63 | 1.14 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -28.95 | 18.12 | -5.94 | — | — | — | — | — | — | |
| Net Margin | -22.37 | 23.19 | -0.99 | — | — | — | — | — | — | |
| Shares Outstanding | 138 | 84 | 74 | — | — | — | — | — | — | |
| Market Capitalization | 588 | 87 | 115 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CEO | Nov 06 '25 | Option Exercise | 1.59 | 101,793 | 161,851 | 1,191,477 | Oct 16 |
| McCarthy Sean A. | CEO | Nov 06 '25 | Sale | 4.54 | 203,586 | 923,812 | 987,891 | Oct 16 |
| Ogden Christopher | Chief Financial Officer | Jun 15 '26 | Sale | 3.05 | 1,624 | 4,953 | 295,324 | Jun 17 |
| Chu Yu-Waye | Chief Medical Officer | Mar 17 '26 | Sale | 6.42 | 21,279 | 136,675 | 189,446 | Mar 19 |
| McCarthy Sean A. | CEO | Mar 17 '26 | Sale | 6.42 | 118,969 | 764,138 | 1,078,922 | Mar 19 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Mar 17 '26 | Sale | 6.42 | 31,492 | 202,273 | 300,760 | Mar 19 |
| Ogden Christopher | Chief Financial Officer | Mar 17 '26 | Sale | 6.42 | 19,323 | 124,112 | 296,948 | Mar 19 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Jun 16 '25 | Sale | 2.69 | 13,884 | 37,334 | 272,252 | Jun 17 |
| Ogden Christopher | Chief Financial Officer | Jun 16 '25 | Sale | 2.69 | 10,614 | 28,540 | 226,271 | Jun 17 |
| McCarthy Sean A. | CEO | Jun 16 '25 | Sale | 2.69 | 55,511 | 149,264 | 1,089,684 | Jun 17 |
| McCarthy Sean A. | CEO | Jun 13 '25 | Option Exercise | 0.00 | 150,000 | 0 | 1,145,195 | Jun 17 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Jun 13 '25 | Option Exercise | 0.00 | 37,500 | 0 | 286,136 | Jun 17 |
| Ogden Christopher | Chief Financial Officer | Jun 13 '25 | Sale | 2.95 | 1,641 | 4,841 | 199,385 | Jun 17 |
| Ogden Christopher | Chief Financial Officer | Jun 13 '25 | Option Exercise | 0.00 | 37,500 | 0 | 236,885 | Jun 17 |
| McCarthy Sean A. | CEO | Mar 18 '25 | Sale | 0.60 | 37,656 | 22,556 | 995,195 | Mar 20 |